Parametrica Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parametrica Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,506	Closed	-$425K	–	190
2022 Q1	$425K	Buy	+5,506	New	+$461K	0.32%	67
2020 Q4	–	Sell	-7,196	Closed	-$547K	–	163
2020 Q3	$547K	Buy	+7,196	New	+$728K	1.03%	28
2016 Q3	–	Sell	-6,507	Closed	-$506K	–	142
2016 Q2	$506K	Buy	6,507 +3,898	+149%	+$331K	0.76%	20
2016 Q1	$215K	Buy	+2,609	New	+$212K	0.77%	72
2015 Q4	–	Sell	-3,708	Closed	-$391K	–	68
2015 Q3	$391K	Buy	+3,708	New	+$495K	2.46%	5

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Parametrica Management's BMRN Position: Q2 2022 in Review

Parametrica Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 5,506 shares — an estimated $425K sold.

Parametrica Management first reported a position in BMRN in Q3 2015 and held it in 5 quarters. The position peaked at $547K in Q3 2020. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Parametrica Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Parametrica Management sold 5,506 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $425K.
Parametrica Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Parametrica Management's BioMarin Pharmaceuticals position peaked at $547K in Q3 2020.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.